Bharat Serums and Vaccines (BSV) is one of the leading players in the area of biologics. It was founded by Dr Vinod G Daftary in 1971 to pursue the goal of introducing specialized healthcare products to meet the needs of a quality conscious market.

During FY 2013-14, the revenue performance of BSV stood at Rs 428 crore as compared to Rs 389 crore in FY 2012-13. The growth was over 10 percent. BSV was also recognized as the fastest growing company by Frost & Sullivan in 2012. The company, today researches, develops, manufactures, and markets injectable biological, pharmaceutical, and biotech products. The company holds a formidable market share in India for plasma derivatives and is constantly expanding its range of products by introducing new and improved therapies based on R&D initiatives and efforts.

BSV has three R&D centers located in India, Germany, and USA engaged in research areas mentioned above. It has more than 15 patents and has been a pioneer in making available life-saving products to Indian patients and has commercialized many products for the first time including monoclonal anti D, anti thymocyte globulin, propofol, and anti-snake venom serum. The company has over 700 people selling its products across the country and exports its product range to around 45 countries across the world.

The company currently has two private equity investors, Kotak Private Equity and Orbimed Advisors. There have been indications that Carlyle group is in a discussion to buy the 15 percent stake held in the company by Kotak Mahindra's private equity arm as well as another 8-10 per cent held by OrbiMed Advisors.